Which colonoscopy prep works best for diabetics? new trial aims to find out
NCT ID NCT07351019
First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 3 times
Summary
This study compares two bowel cleansing solutions, Golytely and SUPREP, for colon cancer screening in people with diabetes. Researchers want to see which one cleans the colon better and is easier to tolerate. About 80 participants will be randomly assigned to one of the two preps and then rate their experience. The goal is to improve colonoscopy quality for diabetic patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Golytely and SUPREP (bowel cleansing solutions)
- What this could lead to
- If successful, this study could help doctors choose the best bowel prep for diabetic patients, improving colonoscopy quality and comfort.
- What could go wrong
- This is a small, early-phase trial with only 80 participants, so results may not apply to all diabetics. The study compares existing drugs, not a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
64 people
The number who actually took part.
- Started
-
Jan 2026
- Finished
-
Jul 2026
- Lead sponsor
-
A government agency
The lead sponsor is a US federal agency other than the NIH.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Participants having provided informed consent with signature on informed consent form: the informed consent process should be complete with full discussion of all requirements and possible risks. 2. Diabetic volunteer (defined per current ACP guidelines, and any type of DM) 3. Aged 18+ years, inclusive 4. Average screening risk, polyp surveillance, and family history of cancer Exclusion Criteria: 1. Unable to provide informed consent to participate in the study Such as a mental condition rendering the participant unable to understand the nature, scope, and possible consequences of the study 2. Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult or that would put the participant at risk by participating in the study 3. Persistent significant or severe infection, either acute or chronic 4. Prior use of any investigational drug in the preceding 6 months 5. Liver function impairment or persisting elevations (confirmed by retest) of alanine aminotransferase (ALT), aspartate aminotransferase (AST), or direct bilirubin greater than 2x the upper limit of normal range (ULN). 6. Pregnant or breast-feeding women or those who plan to become pregnant during the study 7. Participants with significantly impaired bone marrow function or significant anemia, leukopenia, or thrombocytopenia (confirmed by retest): 1. Hematocrit \< 35% and/or 2. Absolute white blood cell count \< 3000 cells/mm3 ( L) and/or 3. Platelet count \< 150 000 cells/mm3 ( L) and/or- Absolute neutrophil = 1500 cells/mm3 ( L) 8. History of colorectal cancer 9. Inflammatory Bowel Disease 10. Past surgical history of colon resection 11. Prior history of colorectal surgery 12. Family history of hereditary polyposis and cancer disorders to include but not limited to FAP (Familial Adenomatous Polyposis), Gardner Syndrome, Turcot Syndrome, Lynch Syndrome, Cowden Syndrome, and Peutz-Jeghers Syndrome 13. Symptomatic patients (bleeding, diarrhea, constipation, abdominal pain)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colon cancer screening are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dwight D. Eisenhower Army Medical Center
Fort Gordon, Georgia, 30905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ivosidenib plus mFOLFOXIRI and celecoxib as a treatment for BRAF-targeted therapy-refractory BRAF V600E-mutant colorectal cancer patients: a phase II study
- Can a new drug shrink advanced solid tumors?
- Can diverse tissue samples unlock Obesity's secrets?
- Can a new drug shrink tumors that resist standard care?
- Personalized nursing care may boost diabetes Self-Management
- A single blood draw to detect five cancers before symptoms appear?